GSK plc acquires Sierra Oncology, Inc. (2022)

Deal facts

Buyer: GSK plc
Target: Sierra Oncology, Inc.
Deal value: Not disclosed
Announced: 12 April 2022
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

1 Jul 2022CompletedClosed
GSK plc completes acquisition of Sierra Oncology, Inc.
Introductory Note As previously disclosed, on April 12, 2022, Sierra Oncology, Inc. (which we refer to as the “ Company ” or “ Sierra Oncology ”) entered into an Agreement and Plan of Merger (which we refer to as the “ Merger Agreement ”) with GSK plc (formerly GlaxoSmithKline plc) (which we refer to as “ GSK ”) and Orikum Acquisition Inc. (which we refer to as “ Acquisition Sub ”). Pursuant to th
Source

OpinionExit Mode editorial

We see a clear signal in GSK plc's acquisition of Sierra Oncology, Inc. announced on 12 April 2022. This is a cross-border transaction where a UK listed pharmaceutical giant moves to take a US biotech firm private. The deal structure relies entirely on cash consideration, which removes the complexity of share swaps and provides immediate liquidity for the target shareholders. For the SME founder reading this, the choice of a full cash exit often reflects a buyer's desire to secure control without diluting their own equity base or exposing the combined entity to immediate market volatility.

The classification as a going private deal carries specific regulatory weight in both the US and UK. While the UK Competition and Markets Authority would typically scrutinise such a merger for anti-competitive effects, the primary hurdle here is the US regulatory framework governing the delisting of a public company. The buyer must navigate Securities and Exchange Commission rules to ensure the target can legally cease being a public reporting entity. This process demands rigorous adherence to disclosure standards and often triggers change-of-control covenants in the target's existing debt or partnership agreements that must be resolved before completion. The fact that the deal status is now completed suggests these mechanical and regulatory hurdles were cleared without material obstruction.

We think this transaction highlights a strategic preference for speed and certainty in the healthcare sector. By offering cash, GSK plc bypassed the need for shareholder approval on a share-exchange basis, accelerating the path to integration. This approach is particularly relevant when the target holds proprietary assets that require rapid development or regulatory approval. The absence of an earn-out structure in the public facts implies the buyer has priced in the full value of the target's pipeline at the point of sale. This removes the long-term performance risk for the seller but places the full burden of execution on the acquirer.

The immediate lesson for any founder planning an exit is to prepare your capital structure for a cash deal well before entering negotiations. You must identify and address any change-of-control covenants in your debt facilities or major commercial contracts that could block a cash-only acquisition. Review these agreements this week to ensure no third-party consent is required to proceed, as this is often the single biggest delay in closing a clean cash exit.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2022 deals More going private deals More from GSK plc All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

5 May 2026CompletedHealthcare

Merck to acquire Terns Pharmaceuticals, Inc.

Merck and Terns Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Merck
Target: Terns Pharmaceuticals, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

27 April 2026CompletedHealthcare

BioMarin Pharmaceutical Inc. to acquire Amicus Therapeutics, Inc.

BioMarin Pharmaceutical Inc. and Amicus Therapeutics, Inc. entered the Exit Mode archive.

Buyer: BioMarin Pharmaceutical Inc.
Target: Amicus Therapeutics, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 April 2026CompletedHealthcare

Servier to acquire Day One Biopharmaceuticals, Inc.

Servier and Day One Biopharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Servier
Target: Day One Biopharmaceuticals, Inc.
Deal value: USD 2,500,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

30 March 2026CompletedHealthcare

Aurinia Pharma U.S., Inc. to acquire Kezar Life Sciences, Inc.

Aurinia Pharma U.S., Inc. and Kezar Life Sciences, Inc. entered the Exit Mode archive.

Buyer: Aurinia Pharma U.S., Inc.
Target: Kezar Life Sciences, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 March 2026CompletedHealthcare

Abbott to acquire Exact Sciences Corp

Abbott and Exact Sciences Corp entered the Exit Mode archive.

Buyer: Abbott
Target: Exact Sciences Corp
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

Buyer history

GSK plc

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive

GSK plc to acquire Sierra Oncology, Inc.

Deal facts

Join Exit Mode Insider

Deal timeline

Browse adjacent archives

Similar deals

Merck to acquire Terns Pharmaceuticals, Inc.

BioMarin Pharmaceutical Inc. to acquire Amicus Therapeutics, Inc.

Servier to acquire Day One Biopharmaceuticals, Inc.

Aurinia Pharma U.S., Inc. to acquire Kezar Life Sciences, Inc.

Abbott to acquire Exact Sciences Corp

GSK plc

How this page is built